-$0.30 Earnings Per Share Expected for Aptinyx Inc. (NASDAQ:APTX) This Quarter

Equities research analysts forecast that Aptinyx Inc. (NASDAQ:APTXGet Rating) will report earnings of ($0.30) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Aptinyx’s earnings. The lowest EPS estimate is ($0.39) and the highest is ($0.27). Aptinyx reported earnings of ($0.29) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 3.4%. The company is expected to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Aptinyx will report full-year earnings of ($1.10) per share for the current year, with EPS estimates ranging from ($1.30) to ($1.01). For the next year, analysts expect that the business will post earnings of ($0.84) per share, with EPS estimates ranging from ($1.24) to ($0.30). Zacks’ earnings per share averages are an average based on a survey of research analysts that cover Aptinyx.

Aptinyx (NASDAQ:APTXGet Rating) last released its quarterly earnings data on Thursday, May 12th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.02. During the same quarter in the previous year, the firm posted ($0.22) earnings per share.

APTX has been the topic of several research analyst reports. Truist Financial reduced their price target on shares of Aptinyx from $12.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, April 8th. William Blair cut shares of Aptinyx from an “outperform” rating to a “market perform” rating in a research report on Thursday, April 7th. BMO Capital Markets reduced their price target on shares of Aptinyx from $12.00 to $6.00 in a research report on Friday, April 8th. SVB Leerink dropped their price objective on shares of Aptinyx from $10.00 to $4.00 and set an “outperform” rating on the stock in a research note on Thursday, April 21st. Finally, Cantor Fitzgerald dropped their price objective on shares of Aptinyx from $11.00 to $5.00 and set an “overweight” rating on the stock in a research note on Friday, April 8th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Aptinyx presently has an average rating of “Buy” and a consensus price target of $3.88.

Shares of NASDAQ APTX traded up $0.10 during midday trading on Friday, hitting $0.70. 136,370 shares of the company traded hands, compared to its average volume of 312,910. Aptinyx has a 12-month low of $0.57 and a 12-month high of $4.73. The company has a debt-to-equity ratio of 0.15, a quick ratio of 20.18 and a current ratio of 20.18. The stock has a 50-day moving average price of $1.78 and a 200 day moving average price of $2.43. The firm has a market cap of $47.40 million, a P/E ratio of -0.59 and a beta of 1.46.

Several hedge funds and other institutional investors have recently modified their holdings of APTX. Millennium Management LLC lifted its stake in shares of Aptinyx by 19.7% in the fourth quarter. Millennium Management LLC now owns 1,246,945 shares of the company’s stock worth $3,329,000 after buying an additional 205,553 shares in the last quarter. Point72 Asset Management L.P. bought a new position in Aptinyx during the fourth quarter valued at approximately $448,000. Vanguard Group Inc. lifted its position in Aptinyx by 8.4% during the first quarter. Vanguard Group Inc. now owns 1,964,058 shares of the company’s stock valued at $4,459,000 after purchasing an additional 152,943 shares during the period. Northern Trust Corp lifted its position in Aptinyx by 203.7% during the first quarter. Northern Trust Corp now owns 219,698 shares of the company’s stock valued at $498,000 after purchasing an additional 147,357 shares during the period. Finally, Victory Capital Management Inc. bought a new position in Aptinyx during the first quarter valued at approximately $319,000. Hedge funds and other institutional investors own 55.97% of the company’s stock.

About Aptinyx (Get Rating)

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia.

See Also

Get a free copy of the Zacks research report on Aptinyx (APTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptinyx (NASDAQ:APTX)

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.